Select a year:

Institut de la Vision & 4P-Pharma announce a partnership for the development of an innovative therapy for retinal diseases

4P-Pharma, a clinical-stage biotechnology company and the research center Institut de la Vision (Sorbonne Université, Inserm, CNRS) establish a partnership agreement for the development of 4P020, a promising therapeutic approach for dry age-related macular degeneration (dAMD) and Stargardt disease with the support of the SATT Lutech. This drug candidate, initially studied by Dr Valerie Fontaine at the Institut de la Vision, opens&hellip

Read More